Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors

Edge Therapeutics, Inc.:

We consent to the use of our report dated March 1, 2018, with respect to the balance sheets of Edge Therapeutics, Inc. as of December 31, 2017 and 2016, and the related statements of operations and comprehensive loss, convertible preferred stock and change in stockholders’ equity (deficit), and cash flows for each of the years in the three year period ended December 31, 2017, and the related notes (collectively, the “financial statements”) incorporated herein by reference.

/s/ KPMG LLP

Short Hills, New Jersey

March 2, 2018